Repligen Corporation Stock News

Brokerages forecast that Repligen Co. will report $183.55 million in sales for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Repligen''s…

Smart Beta ETF report for RFG

Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.

Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

Needham lowered Fiverr International Ltd. (NYSE: FVRR) price target from $205 to $100. Fiverr International shares gained 2% to $80.00 in pre-market trading. Wedbush cut the price target on Shake S

Repligen Corp (NASDAQ: RGEN ) reported Q4 FY21 sales of $186.5 million , up 72% Y/Y as reported and 73% at constant currency, with organic growth of 69%, beating the consensus of $179.29 million. The base business accounted for 64% of revenue, COVID-related sales accounted for 33% of revenue, and … Full story available on Benzinga.com

Repligen (RGEN) delivered earnings and revenue surprises of 24.62% and 3.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel In Late March Amylyx Pharma

Repligen press release (RGEN): Q4 Non-GAAP EPS of $0.81 beats by $0.16.Revenue of $186.52M (+71.7% Y/Y) beats by $8.25M.For FY2022, the company expects total revenue is expected to…

— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72%

— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72%

Repligen (RGEN) CEO, Tony Hunt on Q4 2021 Results - Earnings Call Transcript

Repligen (RGEN) delivered earnings and revenue surprises of 24.62% and 3.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • Palantir Technologies (NYSE: PLTR ) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. • Organon (NYSE: OGN ) is expected to report quarterly earnings at $1.24 per share on revenue of $1.57 billion. • Perella Weinberg Partners (NASDAQ: PWP ) is likely to report quarterly earnings at $0.30 per share on revenue of $193.75 million. • Navios Maritime Partners (NYSE: NMM ) is estimated to report quarterly earnings at $4.35 per share on revenue of $272.59 million. • Portland General Electric (NYSE: POR ) is likely to report quarterly earnings at $0.76 per share on revenue of $533.13 million. • Frontline (NYSE: FRO ) is estimated to report quarterly earnings at $0.13 per share on revenue of $111.30 million. • R1 RCM (NASDAQ: RCM ) is estimated to report quarterly earnings at $0.11 per share on revenue of $399.26 million. • Fiverr International (NYSE: FVRR ) is likely to report quarterly earnings at $0.04 per share on revenue of $76.